A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARα agonist with potent lipid-lowering activity [2]

Journal of Medicinal Chemistry

Volumn 42, Issue 19, 1999, Pages 3785-3788

  Brown, Peter J ^a   Winegar, Deborah A ^a   Plunket, Kelli D ^a   Moore, Linda B ^a   Lewis, Michael C ^a   Wilson, Joan G ^a   Sundseth, Scott S ^a   Koble, Cecilia S ^a   Wu, Zhengdong ^b   Chapman, James M ^b   Lehmann, Jürgen M ^a   Kliewer, Steven A ^a   Willson, Timothy M ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; CLOFIBRATE; CLOFIBRIC ACID; FENOFIBRATE; FENOFIBRIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; UNCLASSIFIED DRUG; UREIDO THIOISOBUTYRIC ACID;

DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LETTER;

ANIMALS; ANTILIPEMIC AGENTS; BUTYRIC ACIDS; DNA-BINDING PROTEINS; HUMANS; LIPID METABOLISM; MALE; MICE; NUCLEAR PROTEINS; PHENYLUREA COMPOUNDS; PROCETOFEN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; ZINC FINGERS;

EID: 0033598445     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9903601     Document Type: Letter

References (25)

1. Grundy, S. M. Hypertriglyceridemia, Atherogenic Dyslipidemia, and the Metabolic Syndrome. Am. J. Cardiol. 1998, 81, 18B-25B.
2. Staels, B.; Dallongeville, J.; Auwerx, J.; Schoonjans, K.; Leitersdorf, E.; Fruchart, J.-C. Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. Circulation 1998, 98, 2088-2093.
3. Oliver, M. F.; Heady, J. A.; Morris, J. N.; Cooper, J. WHO Cooperative Trial on the Primary Prevention of Ischemic Heart Disease with Clofibrate to Lower Serum Cholesterol: Final Mortality Follow-up. Lancet 1984, 2, 600-604.
4. Ericsson, C.-G.; Nilsson, J.; Grip, L.; Svane, B.; Hamsten, A. Effect of Bezafibrate Treatment over Five Years on Coronary Plaques Causing 20% to 50% Diameter Narrowing (the Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am. J. Cardiol. 1997, 80, 1125-1129.
5. Ruotolo, G.; Ericsson, C.-G.; Tettamanti, C.; Karpe, F.; Grip, L.; Svane, B.; Nilsson, J.; De Faire, U.; Hamsten, A. Treatment Effects on Serum Lipoprotein Lipids, Apolipoproteins and Low-Density Lipoprotein Particle Size and Relationships of Lipoprotein Variables to Progression of Coronary Artery Disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J. Am. Coll. Cardiol. 1998, 32, 1648-1656.
6. Malmendier, C. L.; Lontie, J. F.; Delcroix, C.; Dubois, D. Y.; Magot, T.; De Roy, L. Apolipoproteins C-II and C-III Metabolism in Hypertriglyceridemic Patients. Effect of a Drastic Triglyceride Reduction by Combined Diet Restriction and Fenofibrate Administration. Atherosclerosis 1989, 77, 139-149.
7. Shepherd, J. Lipoprotein Metabolism: an Overview. Drugs 1994, 47, 1-10.
8. Gaw, A.; Packard, C. J.; Shepherd, J. Fibrates. Handbk. Exp. Pharmacol. 1994, 109, 325-348.
9. Issemann, I.; Green, S. Activation of a Member of the Steroid Hormone Receptor Superfamily by Peroxisome Proliferators. Nature 1990, 347, 645-650.
10. Hertz, R.; Bishara-Shieban, J.; Bar-Tana, J. Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs. Suppression of Apolipoprotein C-III. J. Biol. Chem. 1995, 270, 13470-13475.
11. Staels, B.; Vu-Dac, N.; Kosykh, V. A.; Saladin, R.; Fruchart, J.-C.; Dallongeville, J.; Auwerx, J. Fibrates Downregulate Apolipoprotein C-III Expression Independent of Induction of Peroxisomal Acyl Coenzyme A oxidase: a Potential Mechanism for the Hypolipidemic Action of Fibrates. J. Clin. Invest. 1995, 95, 705-712.
12. Haubenwallner, S.; Essenburg, A. D.; Barnett, B. C.; Pape, M. E.; DeMattos, R. B.; Krause, B. R.; Minton, L. L.; Auerbach, B. J.; Newton, R. S.; Leff, T.; Bisgaier, C. L. Hypolipidemic Activity of Select Fibrates Correlates to Changes in Hepatic Apolipoprotein C-III Expression: a Potential Physiologic Basis for their Mode of Action. J. Lipid Res. 1995, 36, 2541-2551.
13. Willson, T. M.; Wahli, W. Peroxisome Proliferator-activated Receptor Agonists. Curr. Opin. Chem. Biol. 1997, 1, 235-241.
14. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A. An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARy). J. Biol. Chem. 1995, 270, 12953-12956.
15. Willson, T. M.; Cobb, J. E.; Cowan, D. J.; Wiethe, R. W.; Correa, I. D.; Prakash, S. R.; Beck, K. D.; Moore, L. B.; Kliewer, S. A.; Lehmann, J. M. The Structure-Activity Relationship between Peroxisome Proliferator-Activated Receptor γ Agonism and the Anti-Hyperglycemic Activity of Thiazolidinediones. J. Med. Chem. 1996, 39, 665-668.
16. Schoonjans, K.; Staels, B.; Auwerx, J. Role of the Peroxisome Proliferator-activated Receptor (PPAR) in Mediating the Effects of Fibrates and Fatty Acids on Gene Expression. J. Lipid Res. 1996, 37, 907-925.
17. Matsui, H.; Okumura, K.; Kawakami, K.; Hibino, M. Improved Insulin Sensitivity by Bezafibrate in Rats. Relationship to Fatty Acid Composition of Skeletal-muscle Triglycerides. Diabetes 1997, 46, 348-353.
18. Kliewer, S. A.; Sundseth, S. S.; Jones, S. A.; Brown, P. J.; Wisely, G. B.; Koble, C.; Devchand, P.; Wahli, W.; Willson, T. M.; Lenhard, J. M.; Lehmann, J. M. Fatty Acids and Eicosanoids Regulate Gene Expression through Direct Interactions with Peroxisome Proliferator-activated Receptors α and γ. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4318-4323.
19. Brown, P. J.; Smith-Oliver, T. A.; Charifson, P. S.; Tomkinson, N. C. O.; Fivush, A. M.; Sternbach, D. D.; Wade, L. E.; Orband-Miller, L.; Parks, D. J.; Blanchard, S. G.; Kliewer, S. A.; Lehmann, J. M.; Willson, T. M. Identification of Peroxisome Proliferator-activated Receptor Ligands from a Biased Chemical Library. Chem. Biol. 1997, 4, 909-918.
20. Hawke, R. L.; Chapman, J. M.; Winegar, D. A.; Salisbury, J. A.; Welch, R. M.; Brown, A.; Franzmann, K. W.; Sigel, C. Potent Hypocholesterolemic Activity of Novel Ureido Phenoxyisobutyrates Correlates with their Intrinsic Fibrate Potency and not with their ACAT Inhibitory Activity. J. Lipid Res. 1997, 38, 1189-1203.
21. Brown, P. J.; Hurley, K. P.; Stuart, L. W.; Willson, T. M. Generation of Secondary Alkylamines on Solid Support by Borane Reduction. Application to the Parallel Synthesis of PPAR ligands. Synthesis 1997, 778-782.
22. Newton, R. S.; Krause, B. R. Mechanisms of Action of Gemfibrozil: Comparison of Studies in the Rat to Clinical Efficacy. In Pharmacological Control of Hyperlipidaemia; Fears, R., Ed.; J. R. Prous: Barcelona, 1986; pp 171-186.
23. (a) Torra, I. P.; Gervois, P.; Staels, B. Peroxisome Proliferator-activated Receptor Alpha in Metabolic Disease, Inflammation, Atherosclerosis and Aging. Curr. Opin. Lipidol. 1999, 10, 151-159.
24. (b) Staels, B.; Winegar, D. A. Unpublished results.
25. The solid-phase chemistry developed for the ureido-fibrates (ref 21) can be used to optimize potency and selectivity of the ureido-TiBAs for human PPARα. Stuart, L. W.; Brown, P. J.; Willson, T. M. Unpublished results.